Written by Keen Meds · Reviewed by Licensed Clinical Providers · March 1, 2026
Key Insight: Polycythemia (elevated red blood cell concentration) occurs in 2 to 5% of men on testosterone therapy. The established clinical action threshold is hematocrit at or above 54% -- above this level, blood viscosity increases in ways that may raise clotting risk.
Of all the monitoring parameters associated with testosterone replacement therapy, hematocrit is the one most men are unfamiliar with before they begin treatment. Testosterone raises red blood cell production -- this is a known, expected pharmacological effect. In the majority of men on appropriately dosed therapy, the resulting hematocrit rise stays well within a normal or acceptable range. In a minority of men, it rises enough to become clinically significant. Understanding why this happens, what threshold triggers concern, and how it is managed -- as well as which delivery methods carry lower risk -- is important for any man starting or considering testosterone therapy.
What Polycythemia Is and Why It Matters
Polycythemia, or erythrocytosis, refers to an elevated concentration of red blood cells in the blood. The most practical clinical measure is hematocrit -- the fraction of blood volume occupied by red blood cells, expressed as a percentage. Normal adult male hematocrit ranges from approximately 38% to 50%. When hematocrit rises substantially above this range, blood viscosity increases.
Viscosity is the resistance of a fluid to flow. Water is thin and low-viscosity. Blood, which carries solid cells suspended in plasma, is thicker by nature. When hematocrit rises, more cells are suspended in the same volume of plasma, making blood measurably thicker and harder to pump through vessels.
The clinical concern with elevated hematocrit is not the thickness itself as a direct harm -- rather, it is that thicker, more viscous blood flows more slowly through vessels, particularly the slow-moving venous system. Slow venous flow is one of three components of Virchow's Triad, the classical model for what predisposes blood to clot: stasis (slow flow), endothelial injury, and a hypercoagulable state. Elevated hematocrit contributes to the stasis component, which in theory increases the risk of venous thromboembolism (DVT and PE).
The clinical action threshold -- hematocrit at or above 54% -- is the level at which major clinical guidelines recommend intervening. It is derived from physiological models of the relationship between hematocrit and blood viscosity, as well as clinical convention that has been validated by decades of TRT monitoring practice.
The Biological Mechanism: How Testosterone Raises Hematocrit
Testosterone's effect on red blood cell production is mediated primarily through erythropoietin (EPO). Erythropoietin is a hormone produced primarily in the kidneys that signals the bone marrow to produce more red blood cells. It is the same hormone that some competitive athletes have historically abused to artificially boost red blood cell counts and oxygen-carrying capacity.
Testosterone stimulates erythropoietin production in the kidneys through androgen receptor-mediated pathways. Higher testosterone levels produce more EPO signaling, which drives more red blood cell production in the bone marrow, which raises hematocrit. This is not a side effect in the traditional sense -- it is a physiologically normal response to testosterone. The testes, androgens, and erythropoiesis are biologically linked.
Testosterone also has direct effects on bone marrow hematopoietic progenitor cells through androgen receptors on these cells, contributing to increased red blood cell production independently of EPO. The combined EPO-mediated and direct marrow effects explain why hematocrit can rise more with TRT than one might predict from EPO signaling alone.
Who Is at Higher Risk of Clinically Significant Polycythemia
Not all men on TRT will develop meaningful hematocrit elevation. Several factors identify men at higher risk.
Formulation matters significantly. Injectable testosterone -- testosterone cypionate or enanthate administered biweekly, or testosterone undecanoate (Aveed) administered quarterly -- produces supraphysiological testosterone peaks in the days immediately after injection. Because erythropoiesis is dose-dependent, these peaks drive more aggressive red blood cell production than the stable physiological levels produced by daily transdermal testosterone. Men on injectable TRT consistently show higher rates of polycythemia than men on transdermal formulations in comparative studies.
Baseline hematocrit matters. Men who begin TRT with hematocrit already at the higher end of normal (48 to 50%) have less margin before reaching the 54% action threshold.
Sleep apnea is a significant risk factor. Untreated sleep apnea causes periodic drops in blood oxygen (hypoxia) during apneic episodes, which independently stimulates EPO production and raises hematocrit. A man with untreated sleep apnea on TRT is experiencing two simultaneous erythropoietic drivers -- the combination can push hematocrit substantially higher than either alone.
Smoking raises carboxyhemoglobin (a dysfunctional form of hemoglobin that cannot carry oxygen), which causes a compensatory increase in red blood cell production. Smokers on TRT are at higher risk of polycythemia.
Age is a modest independent risk factor. Older men tend to have higher baseline hematocrit, less hematocrit regulatory flexibility, and often have concurrent conditions (sleep apnea, COPD) that add erythropoietic drive.
The Standard Monitoring Protocol
Monitoring hematocrit is not optional in TRT management -- it is a required element of safe care, included in every major clinical guideline.
The standard monitoring schedule is:
Baseline hematocrit before starting TRT, to establish the starting point and identify any pre-existing elevation.
Hematocrit at 3 months after starting therapy, when the erythropoietic effect has reached near-maximum and testosterone levels have stabilized at steady state. This is the critical early check.
Annual hematocrit in stable patients thereafter. Men with prior borderline elevation or other risk factors may need more frequent monitoring.
If hematocrit rises above 54%, treatment must not simply continue unchanged. Clinical options include dose reduction (reducing testosterone dose lowers the erythropoietic stimulus), formulation change to a transdermal route if on injectable (daily transdermal delivery produces lower and more stable levels), therapeutic phlebotomy (blood donation or blood removal by a provider, which directly reduces red blood cell volume), or temporary therapy pause while hematocrit normalizes.
In most men, addressing the formulation or dose resolves clinically significant polycythemia without permanently discontinuing TRT.
Transdermal Testosterone and Lower Polycythemia Risk
The pharmacokinetic advantage of daily transdermal testosterone over injectable TRT is particularly relevant to polycythemia management. Transdermal delivery produces stable testosterone levels in the mid-physiological range without the supraphysiological peaks that follow injections.
Because erythropoiesis is driven by testosterone concentration -- higher peaks drive more EPO and more red blood cell production -- the absence of peaks in the transdermal pharmacokinetic profile translates into a lower rate of polycythemia compared to injectables. Clinical studies comparing formulations confirm that hematocrit elevation is consistently more common and more pronounced with injectable testosterone than with daily transdermal gel or spray.
This is a meaningful practical advantage for men who have elevated baseline hematocrit, sleep apnea, or other polycythemia risk factors. Transdermal delivery does not eliminate polycythemia risk -- some men will still see hematocrit rise above the action threshold -- but it reduces the frequency and severity of that elevation in the population.
Frequently Asked Questions
Is polycythemia from TRT dangerous?
Clinically significant polycythemia -- hematocrit at or above 54% -- is a condition that increases blood viscosity and theoretically raises clotting risk. Whether it causes actual clinical harm depends on the degree of elevation, how long it persists without intervention, and individual risk factors. The reason for monitoring is precisely to identify and address this before it becomes dangerous. When caught early and managed appropriately, TRT-associated polycythemia is a manageable side effect, not a crisis.
Does elevated hematocrit mean I have to stop testosterone therapy?
Not necessarily. Most cases of elevated hematocrit on TRT can be managed by dose reduction, switching to a transdermal formulation, or therapeutic phlebotomy. Permanent discontinuation is typically not the first-line response. If hematocrit cannot be maintained below 54% despite these interventions, or if the patient has additional high-risk features, stopping TRT may be appropriate -- but this is a clinical decision made in partnership between patient and provider.
What is therapeutic phlebotomy and is it safe?
Therapeutic phlebotomy is the removal of blood -- typically 450 to 500 mL per session, the same amount as a standard blood donation -- to directly reduce red blood cell concentration. It is a safe, well-established procedure with a very low complication rate. Donating blood at a blood bank is functionally equivalent and has the additional benefit of contributing to the blood supply. It is often the fastest way to bring a high hematocrit below the action threshold.
Does testosterone spray cause less polycythemia than testosterone gel?
Both spray and gel are daily transdermal delivery systems and produce similar pharmacokinetic profiles -- stable mid-physiological testosterone without supraphysiological peaks. The polycythemia risk reduction relative to injectable testosterone applies equally to both transdermal formats. Any differences between specific spray and gel products would depend on formulation-specific factors rather than the delivery mechanism itself.
What This Means for Your Treatment Decisions
Polycythemia is the most consistently documented side effect of testosterone therapy, but in the context of appropriate monitoring it is manageable and, for most men, not clinically significant. Understanding the 54% action threshold, the monitoring schedule, and the lower risk profile of transdermal delivery helps you have an informed conversation with your provider about managing this aspect of TRT safely.
Keen Meds connects you with licensed clinical providers for a telehealth evaluation and lab review. If your testosterone is clinically low, you may qualify for Testosterone Spray Rx.
